Healthcare professional engagement in Australia

The new Medicines Australia Code of Conduct will increase transparency about the vital role of healthcare professionals in the development and use of new, innovative medicines. Healthcare professionals help to educate patients about medicines and their safe, ongoing use – a bond of trust that we, as a Medicines Australia member company, want to help make even stronger.

Novartis values the expert knowledge of patient behavior and of management of diseases that comes from interactions with the healthcare community, Novartis Pharmaceuticals will disclose details of these engagements on this site. Novartis will provide details of reportable payments or transfers of value to a healthcare professional.

Reportable payments or transfers of value are:

  • Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant
  • Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.

The reports are downloadable below, and these will be available for at least 3 years from the date of publication.

These reports can also now be found on the Medicines Australia Centralised Reporting System here.

Latest Report

Novartis Pharmaceuticals - 1 May 2022 to 31 October 2022 (PDF 501 KB) (CSV 57 KB)

Previous Reports

Novartis Pharmaceuticals - 1 November 2021 to 30 April 2022 (PDF 0.1 MB),(CSV 0.1 MB)

Novartis Pharmaceuticals - 1 May 2021 to 31 October 2021 (PDF 0.1 MB),(CSV 0.1 MB)

Novartis Pharmaceuticals - 1 November 2020 to 30 April 2021 (PDF 0.1 MB),(CSV 0.1 MB)

Novartis Pharmaceuticals - 1 May 2020 to 31 October 2020 (PDF 0.1 MB),(CSV 0.1 MB)

Novartis Pharmaceuticals - 1 November to 30 April 2020 (PDF 0.1 MB),(CSV 0.1 MB)

Novartis Pharmaceuticals - 1 May 2019 to 31 October 2019 (PDF 0.1 MB ),(ZIP 0.1 MB)

To comply with our privacy obligations, the report may be amended from time to time. The reports here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.

For further information about the details in the report, please visit

For access to Novartis’s Privacy Policy please click here.

For access to Novartis’s Global Transparency page please click here.

We believe that greater transparency will increase confidence by patients that the working relationship between the industry and healthcare professionals is ethical and appropriate.